<DOC>
	<DOCNO>NCT01265784</DOCNO>
	<brief_summary>This Phase 2 , randomize , double-blind , double-dummy , multicenter , prospective study ass efficacy , safety , pharmacokinetics two dose regimen TP-434 compare ertapenem treatment adult community-acquired complicate intra-abdominal infection ( cIAIs ) .</brief_summary>
	<brief_title>Study Compare TP-434 Ertapenem Community-acquired Complicated Intra-abdominal Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Intraabdominal Infections</mesh_term>
	<mesh_term>Ertapenem</mesh_term>
	<criteria>Abdominal pain/discomfort onset prior hospitalization Evidence systemic inflammatory response Physical finding consistent intraabdominal infection ( IAI ) Clinical diagnosis communityacquired IAI require urgent surgical percutaneous intervention expect require antibacterial therapy longer 14 day Body mass index ( BMI ) â‰¤ 30 kilogram per square meter ( kg/m^2 ) Able provide inform consent . If participant unable provide inform consent , participant 's legally acceptable representative may provide write consent accordance institutional guideline If female , pregnant nursing , childbearing potential either : commit use least two medically accept , effective method birth control ( example , condom , oral contraceptive , indwell intrauterine device , hormonal implant/patch , injection , approve cervical ring ) study drug dose 90 day follow last study drug dose practice sexual abstinence Symptoms related diagnosis complicate appendicitis ( current diagnosis ) &lt; 24 hour prior current hospitalization Previously hospitalize admit healthcare facility within last 6 month Managed Staged Abdominal Repair open abdomen technique Known study entry IAI cause pathogen ( ) resistant study drug antibiotic Acute Physiology Chronic Health Evaluation ( APACHE ) II score &gt; 25 Unlikely survive 68 week study period Any rapidlyprogressing disease immediately lifethreatening illness , include acute hepatic failure , respiratory failure septic shock Requirement vasopressor therapeutic dosage Renal failure Presence possible sign hepatic disease Hematocrit &lt; 25 % hemoglobin &lt; 8 gram per deciliter ( g/dL ) Neutropenia absolute neutrophil count &lt; 1000 cell per cubic millimeter ( mm^3 ) Platelet count &lt; 50,000/mm3 Abnormal coagulation test participant anticoagulant Immunocompromised condition , include know human immunodeficiency virus ( HIV ) positivity acquire immune deficiency syndrome ( AIDS ) , organ ( bone marrow ) transplant recipient , hematological malignancy . Immunosuppressive therapy , include use highdose corticosteroid ( example , &gt; 40 milligram [ mg ] prednisone equivalent per day great 2 week ) History hypersensitivity reaction tetracyclines carbapenems Participation investigational drug device study within 30 day prior study entry Known suspect central nervous system ( CNS ) disorder may predispose seizure low seizure threshold Previously receive TP434 clinical trial More 24 hour duration systemic antibiotic coverage current condition Received ertapenem carbapenem , tigecycline current infection Need concomitant systemic antimicrobial agent study drug receive systemic ( IV oral ) antibiotics last 3 month Refusal mechanical ventilation , dialysis hemofiltration , cardioversion resuscitative measure drug/fluid therapy time consent Known suspect inflammatory bowel disease associate visceral abscess</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>